Incretin Atlas › Trials › EECOH-2
EECOH-2
Ecnoglutide · t2d
Design
- Molecule(s)
- Ecnoglutide
- Population
- t2d
- Phase
- 3
- Participants
- 623
- Duration
- 32 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.6 mg vs dulaglutide 1.5 mg: HbA1c -1.65 | t2d china | 32 | 623 | — | — | −1.9 | 3.0 | — | — | — | — | — | press release |
| 1.2 mg vs dulaglutide 1.5 mg: HbA1c -1.65 | t2d china | 32 | 623 | — | — | −1.9 | 4.0 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 0.6 mg · hba1c · publication (abstract)
At week 32, mean HbA1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg
- 0.6 mg · ae_dc · publication
six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events
- 1.2 mg · hba1c · publication
1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide.
- 1.2 mg · ae_dc · publication
six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: EECOH-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.